Treatment for late-stage lung cancer sheds new light! Immunotherapy significantly improves survival rates.

Previously, chemotherapy was the only treatment available to patients with late-stage lung cancer who did not have a distinct genetic expression, and targeted therapy was not an option. According to research data, the survival rate is only eight to twelve months.

However, the introduction of immunotherapy marks a shift in previous treatment standards. According to a study presented at the American Society of Clinical Oncology’s annual meeting in Chicago, patients who received first-line tumor immunotherapy combined with chemotherapy had significantly longer survival times, regardless of their level of PD-L1 expression. It is almost twice as effective as chemotherapy alone!

According to the most recent three-year tracking data from the World Conference on Lung Cancer, if patients’ PD-L1 expression exceeds 50%, the first-line independent use of immunotherapy will produce better results than chemotherapy.

【Article Report】

A new way to treat lung cancer: cancer immunotherapy combined with chemotherapy.
Targeted drugs in treating lung cancer: maintaining patients’ and their families’ quality of life
Cancer immunotherapy combined with chemotherapy: a new approach to treating lung cancer
The female patient with lung cancer had run out of treatment options and was saved by immunotherapy.

【Video Interview】

Learn about lung cancer classification, genetic testing, and treatment options.
Should I get a genetic test for cancer?What factors should be considered?

Dr. Wu Ming-Fang

Attending physician, Department of Chest Medicine

Main Info